http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kang, Ji-Hun,Wang, Sheng,Shi, Zhiwen,Zhao, Wenyu,Yablonovitch, Eli,Wang, Feng American Chemical Society 2017 NANO LETTERS Vol.17 No.3
<P>Two-dimensional surface polaritons (2DSPs), such as graphene plasmons, exhibit various unusual properties, including electrical tunability and strong spatial confinement with high Q-factor, which can enable tunable photonic devices for deep subwavelength light manipulations. Reflection of plasmons at the graphene’s edge plays a critical role in the manipulation of 2DSP and enables their direct visualization in near-field infrared microscopy. However, a quantitative understanding of the edge-reflections, including reflection phases and diffraction effects, has remained elusive. Here, we show theoretically and experimentally that edge-reflection of 2DSP exhibits unusual behaviors due to the presence of the evanescent waves, including an anomalous Goos-Hänchen phase shift as in total internal reflections and an unexpected even–odd peak amplitude oscillation from the wave diffraction at the edge. Our theory is not only valid for plasmons in graphene but also for other 2D polaritons, such as phonon polaritons in ultrathin boron nitride flakes and exciton polariton in two-dimensional semiconductors.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/nalefd/2017/nalefd.2017.17.issue-3/acs.nanolett.6b05077/production/images/medium/nl-2016-050772_0005.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/nl6b05077'>ACS Electronic Supporting Info</A></P>
Xueying Li,He Huang,Bing Xu,Hongqiang Guo,Yingcheng Lin,Sheng Ye,Jiqun Yi,Wenyu Li,Xiangyuan Wu,Wei Wang,Hongyu Zhang,Derong Xie,Jiewen Peng,Yabing Cao,Xingxiang Pu,Chengcheng Guo,Huangming Hong,Zhao 대한암학회 2019 Cancer Research and Treatment Vol.51 No.3
Purpose Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP (R-CHOP-14) could improve the outcome of the disease in Asian population. Materials and Methods Newly diagnosed DLBCL patients were centrally, randomly assigned (1:1) to receive R-CHOP- 14 or R-CHOP-21. R-CHOP-14 was administered every 2 weeks, and R-CHOP-21 was administered every 3 weeks. Primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), progression-free survival (PFS), response rate and toxicities. Results Seven hundred and two patients were randomly assigned to receive R-CHOP-14 (n=349) or R-CHOP-21 (n=353). With a median follow-up of 45.6 months, the two groups did not differ significantly in 3-year DFS (79.6% for R-CHOP-14 vs. 83.2% for R-CHOP-21, p=0.311), 3-year OS (77.5% for R-CHOP-14 vs. 77.6% for R-CHOP-21, p=0.903), or 3-year PFS (63.2% for R-CHOP-14 vs. 66.1% for R-CHOP-21, p=0.447). Patients with an International Prognostic Index (IPI) score ! 2 had a poorer prognosis compared to those with an IPI score < 2. Grade 3/4 hematologic and non-hematologic toxicities were manageable and similar between R-CHOP-14 and R-CHOP-21. Conclusion R-CHOP-14 did not improve the outcome of DLBCL compared to R-CHOP-21 in Asian population. With manageable and similar toxicities, both of the two regimens were suitable for Asian DLBCL patients. For high-risk patients with IPI ! 2, new combination regimens based on R-CHOP deserve further investigation to improve efficacy.